



INVEST LIKE A PRO, WITH THE PROS!





We received an enlightening update Wednesday on the cannabis oils and concentrates extraction business of **Halo Labs (NEO:HALO)** from CEO *Kiran Sidhu* for a video we'll post next week.

The impact of their expanding California

operations. It's big play in Lesotho. Revenue and profitability projections. What investors are missing in this undervalued stock. Sidhu covers it all.

Don't miss it.

www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

July 25, 2019

Written & compiled by Mark Bunting, Publisher,
Capital Ideas Media



CANADIAN ANALYSTS' CALLS

INITIATIONS

Valens GroWorks (TSXV:VGW). Eight Capital starts coverage on one of our favourite cannabis extraction companies with a "buy" rating and price target of \$8.25 (Canadian), implying **112% upside**. The stock closed Wednesday at \$3.88.

MedMen Enterprises (CSE:MMEN) Roth Capital starts with a "buy" on the cannabis retailer and a target of \$5.

**

CargoJet (TSX:CJT). Canaccord Genuity remains bullish on the company but lowers its rating to "hold" from buy strictly on valuation, saying the shares are "*getting the premium valuation they deserve*" ahead of quarterly earnings on July 31. The price target is raised to \$100 from \$95.

CargoJet shares are up 24% since the last earnings release and **nearly 37% since our December 18, 2018 cover story.**

theScore (TSXV:SCR). Mackie Research maintains "buy" and a price target of \$0.70, which **implies an 84% gain**, after the company delivered record Q3 revenue, and ahead of the launch of its sports betting app expected in time for the NFL season.

theScore had a quarterly net loss of \$1.7 million versus a loss of \$894,000 a year ago, which was due mostly to additional expenses related to the ongoing development of its sports betting business.

Loblaw (TSX:L). Desjardins Securities lifts the target to \$73 from \$70 and maintains a "buy"

after the retailer released earnings results.

Curaleaf (CSE:CURA). Beacon Securities maintains "buy" and a target of \$25, implying **164% upside**, saying the recent dip in the stock is a "*strong buying opportunity*".

Beacon says Curaleaf was "*issued a warning letter from the U.S. Food and Drug Administration (FDA) wherein the FDA alleged that CURA is selling CBD products that make unsubstantiated therapeutic claims...We expect the remedial action required to relate to repackaging/rewording, and given the fact that this product line was only recently launched, the associated cost should be minimal.*"



U.S. ANALYSTS' CALLS

Facebook (NASDAQ:FB). Canaccord Genuity ups the target to \$240 (U.S.) from \$225 citing solid Q2 earnings results, stable user trends and accelerating advertising revenue growth. See more on FB's earnings below.

STOCKS THAT MAY MOVE

Suncor Energy (TSX:SU) reported a 5% increase in Q2 operating profit and record

production of 803,900 barrels of oil equivalent per day.

Teck Resources (TSX:TECK.B;NYSE:TECK) reported quarterly profit slightly below analyst estimates, hurt by the ongoing U.S.-China trade war and slowing macroeconomic outlook, which have caused lower copper and zinc prices.

Nokia (NYSE:NOK) shares are surging in pre-market trading on an earnings beat and an improved outlook from the networking company.

Facebook (NASDAQ:FB) is up 2% in pre-market trading after the social media giant's revenue beat market estimates. But Facebook warned revenue growth could slow and costs could rise due to new data privacy rules.

Anheuser-Busch InBev (NYSE:BUD) beat earnings estimates thanks to its strongest beer sales in five years. BUD is still sitting on more than \$104 billion in debt.

Raytheon (NYSE:RTN) beat estimates and raised its forecast. The weapons maker is in the process of being bought by **United Technologies (NYSE:UTX)**.

Salesforce.com (NYSE:CRM) said that "Alibaba will become the exclusive provider of Salesforce to customers in mainland China, Hong Kong, Macau

and Taiwan, and Salesforce will become the exclusive enterprise CRM product suite sold by Alibaba."

Tesla (NASDAQ:TSLA) shares are down about 10% after the electric car maker missed quarterly revenue estimates. The company also said its chief technology officer is stepping down.

MARKETS

S&P/TSX and U.S. equity futures are mixed to higher amid a slew of earnings reports, signals from the European Central Bank that it stands ready to ease monetary policy, and ahead of results expected after the closing bell from Amazon and Google.

Both the S&P 500 and Nasdaq Composite hit record levels yesterday while French stocks are at a 12-year high led by LVMH.

In economic data, U.S. business equipment orders jumped the most since early 2018.

CURRENCIES

The Canadian dollar is inching higher at \$0.7621 (U.S.).

COMMODITIES

West Texas Intermediate is up 1.9% to \$56.92 a

barrel.

Gold is up slightly at \$1,424.60 an ounce.

DAILY UPDATE

Our main investment idea in the new [Capital Ideas Digest](#) delivers a steady diet of steady growth.

20%+ revenue and EBITDA growth annually over 10 years, with the stock growing 30% annually over that time.

The article features several charts detailing the company's business.

Plus, check out the **the best way to trade the silver breakout.**

Capital Ideas Media provides marketing services to Halo Labs.

Please email questions, comments or concerns to: customercare@capitalideasresearch.com

Access, ideas and insight.

Mark Bunting
Publisher,
Capital Ideas Media

www.capitalideasmedia.com



The information and recommendations made available here (“Information”) by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any

person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

[Add us to your address book](#)

[update subscription preferences](#)

This email was sent to <<Email Address>>

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada
